Patented technology further personalizes total knee arthroplasty for surgeons and patients
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue’s technology allows surgeons using Smith+Nephew’s CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency.
Pre-operative surgical planning provides the surgeon with information about the patient's anatomy to help the surgeon determine the preferred implants before the surgery begins. This foresight helps to enable just-in-time delivery of implants and instruments, helping to conserve space and reduce both operating room (OR) time and sterilization costs. The combination of JointVue’s OrthoSonic technology with Smith+Nephew’s CORI Surgical System, known for its small footprint and scalability, offers an ideal solution for Ambulatory Surgery Centers (ASCs) where OR space is limited.
The CORI Surgical System stands out in the market with its image-agnostic registration capabilities, offering both image-free and MRI-powered options for pre-operative planning. Now, with the exclusive adoption of JointVue’s OrthoSonic 3D Surgery Planning Technology for Smith+Nephew implants, surgeons have access to an additional procedural solution that utilizes ultrasound to generate a 3D plan within minutes. This radiation-free, automated planning tool guides surgeons to tailor the procedure uniquely to each patient.
“JointVue’s OrthoSonic technology allows surgeons and patients to get a 3D look inside their knee at the clinic in minutes without radiation - replacing a trip to the imaging center as they get ready for surgery,” said Steven MacDonald, MD, and CEO of JointVue. “The 3D image and automated planning tool helps orthopaedic surgeons personalize the procedure uniquely for each patient.”
As the field of robotic-assisted knee surgery continues to evolve, the demand for solutions that cater to diverse patient profiles, coupled with advanced planning and execution tools, is paramount in personalizing surgery. Robotic-assisted surgery can significantly enhance accuracy and reproducibility, potentially leading to improved patient outcomes compared to conventional techniques.1-3
“The addition of JointVue’s technology further expands the imaging modalities available to Smith+Nephew customers for pre-op robotic planning,” said Mayank Shandil, Global SVP of Recon and Robotics Marketing for Smith+Nephew. “The combination of JointVue with the CORI Surgical System for robotic-assisted knee replacement provides a personalized solution for surgeons and patients and is a perfect fit for the growing ASC market.”
To learn more about the CORI Surgical System and Smith+Nephew’s digital surgery applications across a range of joint arthroplasty indications, please visit https://www.smith-nephew.com/en/health-care-professionals/products/orthopaedics/cori
- ends –
Media Enquiries
Dave Snyder +1 (978) 749-1440
Smith+Nephew david.snyder@smith-nephew.com
References
- Matsumoto T, Nakano N, Hayashi S, et al. Prosthetic orientation, limb alignment, and soft tissue balance with bi-cruciate stabilized total knee arthroplasty: a comparison between the handheld robot and conventional techniques. International Orthopaedics 2023;47(6):1473-80. doi: 10.1007/s00264-023-05737-6
- Crizer MP, Haffar A, Battenberg A, et al. Robotic Assistance in Unicompartmental Knee Arthroplasty Results in Superior Early Functional Recovery and Is More Likely to Meet Patient Expectations. Advances in Orthopedics 2021;2021 doi: 10.1155/2021/4770960
- Negrín R, Duboy J, Iñiguez M, et al. Robotic-assisted vs conventional surgery in medial unicompartmental knee arthroplasty: a clinical and radiological study. Knee Surg Relat Res 2021;33(1):5. doi: 10.1186/s43019-021-00087-2 [published Online First: 2021/02/14]
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.
For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.
◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.
source: Smith & Nephew UK Ltd
【與拍賣官看藝術】走進Sotheby's Maison睇睇蘇富比旗艦藝廊！蘇富比如何突破傳統成規？► 即睇
